Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Ann Hepatol ; 15(1): 41-6, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26626639

RESUMO

INTRODUCTION: Biliary complications can cause morbidity, graft loss, and mortality after liver transplantation. The most troublesome biliary complications are ischemic-type biliary lesions (ITBL), which occur since transplants can now be performed after the donor has undergone circulatory death. The exact origin of this type of biliary complication remains unknown. MATERIAL AND METHODS: A total of 528 patients were retrospectively analyzed following liver transplantation after excluding 30 patients with primary sclerosing cholangitis and those lost to follow-up from January 2007 to January 2014. The incidence of and risk factors for ITBL were evaluated. RESULTS: Cold ischemia time (CIT) (P = 0.042) and warm ischemia time (WIT) (P = 0.006) were found to be independent risk factors for the development of ITBL. Use of the cytochrome P450 (CYP) 3A5 genotype assay to guide individualization of immunosuppressive medications resulted in significantly fewer ITBL (P = 0.027. Autoimmune hepatitis might be a risk factor for ITBL, as determined using univariate analysis (P = 0.047). CONCLUSIONS: Efforts should be taken to minimize risk factors associated with ITBL, such as CIT and WIT. The CYP3A5 genotype assay should be used to guide selection of immunosuppressive therapy in an effort to reduce the occurrence of ITBL.


Assuntos
Doenças Biliares/etiologia , Isquemia/etiologia , Transplante de Fígado/efeitos adversos , Adulto , Doenças Biliares/diagnóstico , Doenças Biliares/prevenção & controle , China , Isquemia Fria/efeitos adversos , Citocromo P-450 CYP3A/genética , Citocromo P-450 CYP3A/metabolismo , Genótipo , Humanos , Imunossupressores/efeitos adversos , Imunossupressores/farmacocinética , Isquemia/diagnóstico , Isquemia/prevenção & controle , Pessoa de Meia-Idade , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Fatores de Tempo , Isquemia Quente/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA